Investigation of inflammation related gene polymorphism of the mannose-binding lectin 2 in schizophrenia and bipolar disorder

References

1. 1.↵
   1. Avramopoulos D,
   2. Pearce BD,
   3. McGrath J,
   4. Wolyniec P,
   5. Wang R,
   6. Eckart N, et al.

   Infection and inflammation in schizophrenia and bipolar disorder: a genome wide study for interactions with genetic variation. PloS one 2015; 10: e0116696.

   OpenUrlCrossRef
2. 2.↵
   Consortium SWGotPG. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511: 421–427.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Sklar P,
   2. Ripke S,
   3. Scott LJ,
   4. Andreassen OA,
   5. Cichon S,
   6. Craddock N, et al.

   Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nature genetics 2011; 43: 977.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Aytac HM,
   2. Oyaci Y,
   3. Pehlivan M,
   4. Pehlivan S.

   DNA Methylation Pattern of Gene Promoters of MB-COMT, DRD2, and NR3C1 in Turkish Patients Diagnosed with Schizophrenia. Clinical Psychopharmacology and Neuroscience 2021.
5. 5.↵
   1. Markota M,
   2. Coombes BJ,
   3. Larrabee BR,
   4. McElroy SL,
   5. Bond DJ,
   6. Veldic M, et al.

   Association of schizophrenia polygenic risk score with manic and depressive psychosis in bipolar disorder. Transl Psychiatry 2018; 8: 1–7.

   OpenUrl
6. 6.↵
   1. Erkmen T,
   2. Şahin C,
   3. Arıcıoğlu F.

   Şizofreni’de İnflamatuvar Mekanizmaların Yeri. Journal of Marmara University Institute of Health Sciences 2015; 5: 134–139.

   OpenUrl
7. 7.↵
   1. Fineberg AM,
   2. Ellman LM.

   Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol Psychiatry 2013; 73: 951–966.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Aytac HM,
   2. Pehlivan S.

   Viral Pandemics as Possible Psycho-immunological Causes of Psychiatric Symptoms: From Past to Present. Journal of Advanced Research in Health Sciences 2020; 3: 92–98.

   OpenUrl
9. 9.↵
   1. Muneer A.

   Bipolar disorder: role of inflammation and the development of disease biomarkers. Psychiatry Investig 2016; 13: 18–33.

   OpenUrl
10. 10.↵
    1. Moens L,
    2. Van Hoeyveld E,
    3. Peetermans WE,
    4. De Boeck C,
    5. Verhaegen J,
    6. Bossuyt X.

    Mannose-binding lectin genotype and invasive pneumococcal infection. Hum Immunol 2006; 67: 605–611.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.
    1. Onay H,
    2. Pehlivan M,
    3. Alper S,
    4. Ozkinay F,
    5. Pehlivan S.

    Might there be a link between mannose binding lectin and vitiligo? Eur J Dermatol 2007; 17: 146–148.

    OpenUrlPubMed
12. 12.↵
    1. Gadjeva M,
    2. Takahashi K,
    3. Thiel S.

    Mannan-binding lectin--a soluble pattern recognition molecule. Mol Immunol 2004; 41: 113–121.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Miller C,
    2. Wilgenbusch S,
    3. Michael M,
    4. Chi DS,
    5. Youngberg G,
    6. Krishnaswamy G.

    Molecular defects in the mannose binding lectin pathway in dermatological disease: Case report and literature review. Clin Mol Allergy 2010; 8: 6.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Jensenius J.

    Mannan-binding lectin deficiency is associated with unexplained recurrent miscarriage. Scand J Immunol 1999; 49: 193–196.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Koucký M,
    2. Malíčková K,
    3. Kopřivová H,
    4. Cindrová-Davies T,
    5. Hrbáčková H,
    6. Černý A, et al.

    Low maternal serum concentrations of mannose-binding lectin are associated with the risk of shorter duration of pregnancy and lower birthweight. Scandinavian journal of immunology 2018; 88: e12675.

    OpenUrl
16. 16.↵
    1. Pągowska-Klimek I,
    2. Cedzyński M.

    Mannan-binding lectin in cardiovascular disease. BioMed research international 2014; 2014.
17. 17.↵
    1. De Pascale G,
    2. Cutuli SL,
    3. Pennisi MA,
    4. Antonelli M.

    The role of mannose-binding lectin in severe sepsis and septic shock. Mediators Inflamm 2013; 2013: 625803.

    OpenUrlPubMed
18. 18.↵
    1. Tsutsumi A,
    2. Takahashi R,
    3. Sumida T.

    Mannose binding lectin: genetics and autoimmune disease. Autoimmunity reviews 2005; 4: 364–372.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Association WM.

    World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191–2194.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. First MB,
    2. Spitzer RL,
    3. Gibbon M,
    4. Williams JB.

    User’s guide for the Structured clinical interview for DSM-IV axis I disorders SCID-I: clinician version: American Psychiatric Pub; 1997.
21. 21.↵
    1. Çorapçıoğlu A,
    2. Aydemir Ö,
    3. Yıldız M,
    4. Esen A,
    5. Köroğlu E.

    DSM-IV Eksen I Bozuklukları (SCID-I) için yapılandırılmış klinik görüşme, klinik versiyon. Ankara: Hekimler yayın birliği. 1999.
22. 22.↵
    1. Aytac HM,
    2. Ozdilli K,
    3. Tuncel FC,
    4. Pehlivan M,
    5. Pehlivan S.

    Tumor Necrosis Factor-alpha (TNF-α) -238 G/A Polymorphism Is Associated with the Treatment Resistance and Attempted Suicide in Schizophrenia. Immunol Invest 2020; 1–13.
23. 23.↵
    1. Karadağ F,
    2. Oral ET,
    3. Aran Yalçın F,
    4. Erten E.

    Young mani derecelendirme ölçeğinin Türkiye’de geçerlik ve güvenilirliği. Türk Psikiyatri Dergisi 2001; 13: 107–114.

    OpenUrl
24. 24.↵
    1. Hamilton M.

    A rating scale for depression. J Neurol Neurosurg Psychiatry1960; 23: 56–62.

    OpenUrlFREE Full Text
25. 25.↵
    1. Akdemir A,
    2. Örsel S,
    3. Dağ İ,
    4. Türkçapar H,
    5. İşcan N,
    6. Özbay H.

    Hamilton Depresyon Derecelendirme Ölçeği (HDDÖ)’nin geçerliği, güvenirliği ve klinikte kullanımı. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 1996; 4: 251–259.

    OpenUrl
26. 26.↵
    1. Kay SR,
    2. Fiszbein A,
    3. Opler LA.

    The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–276.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Kostakoğlu A,
    2. Batur S,
    3. Tiryaki A,
    4. Göğüş A.

    Pozitif ve negatif sendrom ölçeğinin (PANSS) Türkçe uyarlamasının geçerlilik ve güvenilirliği. Türk Psikoloji Dergisi 1999; 14: 23–32.

    OpenUrl
28. 28.↵
    1. Guy W

    , editor. ECDEU Assessment Manual for Psychopharmacology. 1976. Rockville, MD (USA). Department of Health, Education, and Welfare.
29. 29.↵
    1. David AS.

    Insight and psychosis. Br J Psychiatry 1990; 156: 798–808.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Arslan S GKB,
    2. Karakılıç H

    . İçgörünün üç bileşenini değerlendirme ölçeği:güvenilirlik ve geçerlik çalışması. Türkiye’de Psikiyatri 2001; 3: 17–24.

    OpenUrl
31. 31.↵
    1. Conley RR,
    2. Kelly DL.

    Management of treatment resistance in schizophrenia. Biol Psychiatry 2001; 50: 898–911.

    OpenUrlCrossRefPubMedWeb of Science
32. 32.↵
    1. Binbay Z,
    2. Solmaz M,
    3. Kurt E.

    Tedaviye Dirençli İki Uçlu Bozukluk. Journal of Mood Disorders 2015; 5.
33. 33.↵
    1. Gao S,
    2. Lu S,
    3. Shi X,
    4. Ming Y,
    5. Xiao C,
    6. Sun J, et al.

    Distingushing between treatment-resistant and non-treatment-resistant schizophrenia using regional homogeneity. Front Psychiatry 2018; 9: 282.

    OpenUrl
34. 34.↵
    1. Sachs GS.

    Treatment-resistant bipolar depression. Psychiatr Clin North Am 1996; 19: 215–236.

    OpenUrlCrossRefPubMedWeb of Science
35. 35.↵
    1. Baysal E,
    2. Oguzkan-Balci S,
    3. Tunc O,
    4. Celenk F,
    5. Deniz M,
    6. Kanlikama M, et al.

    The polymorphisms of the MBL2 and MIF genes associated with Pediatric Cochlear Implant Patients. Int J Pediatr Otorhinolaryngol 2013; 77: 338–340.

    OpenUrl
36. 36.↵
    1. Lee WC,
    2. Wang LY.

    Simple formulas for gauging the potential impacts of population stratification bias. Am J Epidemiol 2008; 167: 86–89.

    OpenUrlCrossRefPubMedWeb of Science
37. 37.↵
    1. Steffensen R,
    2. Thiel S,
    3. Varming K,
    4. Jersild C,
    5. Jensenius JC.

    Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods 2000; 241: 33–42.

    OpenUrlCrossRefPubMedWeb of Science
38. 38.
    1. Lipscombe R,
    2. Sumiya M,
    3. Summerfield J,
    4. Turner M.

    Distinct physicochemical characteristics of human mannose binding protein expressed by individuals of differing genotype. Immunology 1995; 85: 660–667.

    OpenUrlPubMedWeb of Science
39. 39.↵
    1. Madsen HO,
    2. Garred P,
    3. Thiel S,
    4. Kurtzhals J,
    5. Lamm LU,
    6. Ryder LP, et al.

    Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995; 155: 3013–3020.

    OpenUrlAbstract
40. 40.↵
    1. Erol N,
    2. Kılıç C,
    3. Ulusoy M,
    4. Kececi M.

    Mental health profile in Turkey: a main report. Turkish Republic, Ministry of Health, Ankara. 1998: 77–93.
41. 41.↵
    1. Mayilyan KR,
    2. Arnold JN,
    3. Presanis JS,
    4. Soghoyan AF,
    5. Sim RB.

    Increased complement classical and mannan-binding lectin pathway activities in schizophrenia. Neurosci Lett 2006; 404: 336–341.

    OpenUrlCrossRefPubMed
42. 42.↵
    1. Foldager L,
    2. Steffensen R,
    3. Thiel S,
    4. Als TD,
    5. Nielsen HJ,
    6. Nordentoft M, et al.

    MBL and MASP-2 concentrations in serum and MBL2 promoter polymorphisms are associated to schizophrenia. Acta Neuropsychiatr 2012; 24: 199–207.

    OpenUrl
43. 43.↵
    1. Aytac HM,
    2. Oyaci Y,
    3. Yazar MS,
    4. Erol A,
    5. Pehlivan S.

    Association of MIF and MBL2 gene polymorphisms with attempted suicide in patients diagnosed with schizophrenia or bipolar disorder. J Clin Neurosci 2020; 78: 264–268.

    OpenUrl
44. 44.↵
    1. Aytac HM,
    2. Oyaci Y,
    3. Yazar MS,
    4. Pehlivan S.

    Macrophage Migration Inhibitory Factor - 173 G/C Polymorphism is Associated With The Age of Onset and Insight in Schizophrenia in the Turkish Population. Neurol Res 2021; 1–8.
45. 45.↵
    1. Sekar A,
    2. Bialas AR,
    3. de Rivera H,
    4. Davis A,
    5. Hammond TR,
    6. Kamitaki N, et al.

    Schizophrenia risk from complex variation of complement component 4. Nature 2016; 530: 177–183.

    OpenUrlCrossRefPubMed
46. 46.↵
    1. Foldager L,
    2. Kohler O,
    3. Steffensen R,
    4. Thiel S,
    5. Kristensen AS,
    6. Jensenius JC, et al.

    Bipolar and panic disorders may be associated with hereditary defects in the innate immune system. J Affect Disord 2014; 164: 148–154.

    OpenUrl
47. 47.↵
    1. Reginia A,
    2. Kucharska-Mazur J,
    3. Jabłoński M,
    4. Budkowska M,
    5. Dołtegowska B,
    6. Sagan L, et al.

    Assessment of complement cascade components in patients with bipolar disorder. Front Psychiatry 2018; 9: 614.

    OpenUrl
48. 48.↵
    1. Li WJ,
    2. Kou CG,
    3. Yu Y,
    4. Sun S,
    5. Zhang X,
    6. Kosten TR, et al.

    Association of catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population. Am J Med Genet B Neuropsychiatr Genet 2012; 159B: 370–375.

    OpenUrl
49. 49.↵
    1. Lahdelma L,
    2. Ahokas A,
    3. Andersson LC,
    4. Suvisaari J,
    5. Hovatta I,
    6. Huttunen MO, et al.

    Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. J Clin Psychopharmacol 2001; 21: 4–7.

    OpenUrlPubMed
50. 50.↵
    1. Lahdelma L,
    2. Koskimies S.

    Impact of HLA haplotype on the response to antipsychotic treatment of schizophrenia. Current Pharmacogenomics 2004; 2: 149–155.

    OpenUrl
51. 51.↵
    1. Drago A,
    2. Giegling I,
    3. Schafer M,
    4. Hartmann AM,
    5. Konte B,
    6. Friedl M, et al.

    Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment. Pharmacogenet Genomics 2014; 24: 314–319.

    OpenUrlCrossRefPubMedWeb of Science
52. 52.↵
    1. Geoffroy PA,
    2. Bellivier F,
    3. Leboyer M,
    4. Etain B.

    Can the response to mood stabilizers be predicted in bipolar disorder? Front Biosci (Elite Ed) 2014; 6: 120–138.

    OpenUrl
53. 53.↵
    1. Rybakowski JK,
    2. Czerski P,
    3. Dmitrzak-Weglarz M,
    4. Kliwicki S,
    5. Leszczynska-Rodziewicz A,
    6. Permoda-Osip A, et al.

    Clinical and pathogenic aspects of candidate genes for lithium prophylactic efficacy. J Psychopharmacol 2012; 26: 368–373.

    OpenUrlCrossRefPubMedWeb of Science
54. 54.↵
    1. Panaccione I,
    2. Spalletta G,
    3. Sani G.

    Neuroinflammation and excitatory symptoms in bipolar disorder. Neuroimmunol Neuroinflammation 2015; 2: 215–227.

    OpenUrl
55. 55.↵
    1. Bosetti F,
    2. Weerasinghe GR,
    3. Rosenberger TA,
    4. Rapoport SI.

    Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. J Neurochem 2003; 85: 690–696.

    OpenUrlCrossRefPubMedWeb of Science
56. 56.↵
    1. Akcan U,
    2. Karabulut S,
    3. Küçükali Cİ,
    4. Çakır S,
    5. Tüzün E.

    Bipolar disorder patients display reduced serum complement levels and elevated peripheral blood complement expression levels. Acta Neuropsychiatr 2018; 30: 70–78.

    OpenUrl
57. 57.↵
    1. Gouvea E,
    2. Ota V,
    3. Noto C,
    4. Santoro M,
    5. Spindola L,
    6. Moretti P, et al.

    Gene expression alterations related to mania and psychosis in peripheral blood of patients with a first episode of psychosis. Transl Psychiatry 2016; 6: e908.

    OpenUrl
58. 58.↵
    1. Bolu A,
    2. Erdem M,
    3. Balikci A,
    4. Bilgen AE,
    5. Akgül EO,
    6. Uzun O, et al.

    The relationship between serum levels of haptoglobin and neopterin and the number of episodes in patients with major depression. Journal of Mood Disorders 2013; 3: 1.

    OpenUrl
59. 59.↵
    1. Moylan S,
    2. Maes M,
    3. Wray NR,
    4. Berk M.

    The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2013; 18: 595–606.

    OpenUrlCrossRefPubMedWeb of Science
60. 60.↵
    1. Lamers F,
    2. Milaneschi Y,
    3. de Jonge P,
    4. Giltay EJ,
    5. Penninx B.

    Metabolic and inflammatory markers: associations with individual depressive symptoms. Psychol Med 2018; 48: 1102–1110.

    OpenUrlCrossRef
61. 61.
    1. Lamers F,
    2. Vogelzangs N,
    3. Merikangas KR,
    4. de Jonge P,
    5. Beekman AT,
    6. Penninx BW.

    Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry 2013; 18: 692–699.

    OpenUrlCrossRefPubMed
62. 62.↵
    1. Lasserre AM,
    2. Glaus J,
    3. Vandeleur CL,
    4. Marques-Vidal P,
    5. Vaucher J,
    6. Bastardot F, et al.

    Depression with atypical features and increase in obesity, body mass index, waist circumference, and fat mass: a prospective, population-based study. JAMA Psychiatry 2014; 71: 880–888.

    OpenUrl